SureTrader
Home > Boards > US OTC > Biotechs > Amarantus Bioscience Holdings Inc. (AMBS)

Amarantus BioScience (AMBS) <u>Price Target $2.25 By Fall</u>

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
BCNstocks Member Profile
Member Level 
Followed By 354
Posts 40,252
Boards Moderated 0
Alias Born 08/28/10
160x600 placeholder
Amarantus Subsidiary MANF Therapeutics Announces Positive Independent Peer-Reviewed Pre-Clinical Data for MANF in Parkinson's.. InvestorsHub NewsWire - 1/29/2018 9:00:00 AM
Amarantus Subsidiary Cutanogen Corporation Announces Issuance of US Patent 14/299,480 Covering ESS, Pigmented ESS and Gene InvestorsHub NewsWire - 1/23/2018 9:08:51 AM
Amarantus Provides Update on Capital Restructuring and Announces Participation in RESI JPM 2018 Convertible securities InvestorsHub NewsWire - 1/9/2018 10:14:42 AM
Amarantus Subsidiary Cutanogen Corporation Announces Patent Issuance in Hong Kong Covering ESS, Pigmented ESS and Gene Therapy InvestorsHub NewsWire - 1/4/2018 9:45:00 AM
Amarantus Subsidiary MANF Therapeutics Announces Patent Issuances in Europe and China Covering MANF as a Treatment and Biomar... InvestorsHub NewsWire - 1/3/2018 8:00:00 AM
Amarantus Subsidiary MANF Therapeutics Announces Retinal Patent Issuances in Europe Covering MANF & CDNF and Positive Data for InvestorsHub NewsWire - 12/26/2017 7:30:00 AM
Amarantus Subsidiary MANF Therapeutics Announces Issuance of Japanese Patent Covering Therapeutic Use of MANF in Treatment of InvestorsHub NewsWire - 12/20/2017 8:45:00 AM
Amarantus Subsidiary MANF Therapeutics Announces Publication in Science Magazine of Positive Animal Data for MANF in Treatment InvestorsHub NewsWire - 12/14/2017 8:00:00 AM
Amarantus Subsidiary MANF Therapeutics Receives Notice of Allowance from U.S. Patent & Trademark Office Covering MANF Treatment InvestorsHub NewsWire - 12/11/2017 8:00:00 AM
Amarantus Subsidiary Elto Pharma Announces the Issuance of Patents in Singapore and New Zealand Parkinson's LID InvestorsHub NewsWire - 12/8/2017 9:42:20 AM
Amarantus Subsidiary Elto Pharma Receives Notice of Allowance for European Patent Application Covering Method of Treating... InvestorsHub NewsWire - 12/5/2017 7:45:00 AM
Termination of Registration of a Class of Security Under Section 12(g) (15-12g) Edgar (US Regulatory) - 12/4/2017 4:29:48 PM
Amarantus Provides Comprehensive Corporate Update Recapitalization plan to use funding mechanisms created under the JOBS Act InvestorsHub NewsWire - 12/1/2017 1:02:56 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/6/2017 11:29:07 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/15/2017 12:09:57 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/9/2017 4:17:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/5/2017 4:58:34 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/17/2017 4:29:46 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/6/2017 9:03:57 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/28/2017 4:04:12 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 3/20/2017 12:13:42 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 3/6/2017 4:20:37 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 3/6/2017 4:20:37 PM
BCNstocks Member Level  Tuesday, 02/26/13 12:36:25 PM
Re: None
Post # of 126982 
Amarantus BioScience (AMBS) Price Target $2.25 By Fall 2013 Forecasts Biotech News Stock Review:

Amarantus BioScience (AMBS) Price Target $2.25 By Fall 2013 Forecasts Biotech News Stock Review. AMBS has a huge upside, look for this small biotech to take off soon on some very good news that we are hearing. By Fall today's share price will only be a distant memory!


http://biotechnewsstockreview.blogspot.com/2013/01/amarantus-bioscience-ambs-price-target.html




Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist